Central Texas MSSP Information
ACO Name and Location
- PQN – Central Texas, LLC
- 950 N Glebe Rd
- Suite 4000
- Arlington, VA 22203
ACO Primary Contact
- Michael Richmond
- 203-994-0559
- mrichmond@priviahealth.com
Organizational Information
ACO Participants:
| ACO Participants | ACO Participant in Joint Venture |
|---|---|
| Texas Health Care, P.L.L.C. (Privia Medical Group NTX) | N |
| Stephenville Medical and Surgical Clinic PA | N |
ACO Governing Body:
| Member | Member’s Voting Power –Expressed as a percentage or number | ||||
|---|---|---|---|---|---|
| Last Name | First Name | Title/Position | Membership Type | ACO Participant TIN Legal Business Name/DBA, if Applicable | |
| Tatum, M.D. | Larry | Director | 1 | ACO Participant Representative | Texas Health Care P.L.L.C./Privia Medical Group NTX |
| Stroman, M.D. | David | Director | 1 | ACO Participant Representative | Texas Health Care P.L.L.C./Privia Medical Group NTX |
| Crudup, M.D. | Travis | Director | 1 | ACO Participant Representative | Texas Health Care P.L.L.C./Privia Medical Group NTX |
| Ledbetter, M.D. | Jason | Director | 1 | ACO Participant Representative | Texas Health Care P.L.L.C./Privia Medical Group NTX |
| Tilkin, D.O. | Lynne | Director | 1 | ACO Participant Representative | Texas Health Care P.L.L.C./Privia Medical Group NTX |
| Torres, M.D. | Michelle | Director | 1 | ACO Participant Representative | Texas Health Care P.L.L.C./Privia Medical Group NTX |
| Parker, M.D. | James | Director | 1 | ACO Participant Representative | Texas Health Care P.L.L.C./Privia Medical Group NTX |
| Maxwell, M.D. | William | Director | 1 | ACO Participant Representative | Texas Health Care P.L.L.C./Privia Medical Group NTX |
| Harvey, M.D. | James | Director | 1 | ACO Participant Representative | N/A |
| Morris | Shawn | Director | 1 | Chief Executive Officer, Privia Health | N/A |
| Mehrotra | Parth | Director | 1 | Chief Executive Officer, Privia Health | N/A |
| Dearmore |
Don |
Director | 1 | Medicare Beneficiary Representative | N/A |
Key ACO Clinical and Administrative Leadership:
- ACO Executive: Larry Tatum, M.D.
- Medical Director: Raymond Blair, M.D.
- Compliance Officer: Dana Fields
- Quality Assurance/Improvement Officer: Lynne Tilkin, D.O.
Associated Committees and Committee Leadership:
| Committee Name | Committee Leader Name & Position |
|---|---|
| Clinical Performance | James Parker, M.D. – Chair |
| Finance Committee | Michelle Torres, M.D. – Chair |
| Infrastructure Committee | Chris Voigt – Chair |
| Membership Committee | Jason Ledbetter, M.D. – Chair |
Types of ACO participants, or combinations of participants, that formed the ACO:
- ACO professionals in a group practice arrangement
Shared Savings and Losses
Amount of Shared Savings/Losses
- Second Agreement Period
- Performance Year 2020, $0
- Performance Year 2019: $1,407,570.88
- Performance Year 2018, $2,232,723
Shared Savings Distribution
- Second Agreement Period
- Performance Year 2020
- Proportion invested in infrastructure: n/a
- Proportion invested in redesigned care processes/resources: n/a
- Proportion of distribution to ACO participants: n/a
- Performance Year 2019
- Proportion invested in infrastructure: 30%
- Proportion invested in redesigned care processes/resources: 25%
- Proportion of distribution to ACO participants: 45%
- Performance Year 2018
- Proportion invested in infrastructure: 30%
- Proportion invested in redesigned care processes/resources: 25%
- Proportion of distribution to ACO participants: 45%
- Performance Year 2020
Quality Performance Results
2020 Quality Performance Results:
| ACO# | Measure Name | Rate | ACO Mean |
|---|---|---|---|
| ACO-43 | Ambulatory Sensitive Condition Acute Composite (AHRQ* Prevention Quality Indicator (PQI #91)) | 0.92 | 0.95 |
| ACO-13 | Falls: Screening for Future Fall Risk | 80.65 | 84.97 |
| ACO-14 | Preventive Care and Screening: Influenza Immunization | 68.49 | 76.03 |
| ACO-17 | Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention | 93.33 | 81.67 |
| ACO-18 | Preventive Care and Screening: Screening for Depression and Follow-up Plan | 59.39 | 71.46 |
| ACO-19 | Colorectal Cancer Screening | 73.48 | 72.59 |
| ACO-20 | Breast Cancer Screening | 72.06 | 74.05 |
| ACO-42 | Statin Therapy for the Prevention and Treatment of Cardiovascular Disease | 81.22 | 83.37 |
| ACO-40 | Depression Remission at Twelve Months | 14.49 | 13.99 |
| ACO-27 | Diabetes Mellitus: Hemoglobin A1c Poor Control | 10.89 | 14.70 |
| ACO-28 | Hypertension (HTN): Controlling High Blood Pressure | 82.37 | 72.87 |
Please note, the ACO-40 Depression Remission at 12 months quality measure is not included in public reporting due to low sample size. The Centers for Medicare & Medicaid Services (CMS) also waived the requirement for ACOs to field a CAHPS for ACOs survey for PY 2020 through the Physician Fee Schedule Final Rule for Calendar Year 2021. Additionally, CMS reverted ACO-8 Risk-Standardized, All Condition Readmission and ACO-38 Risk-Standardized Acute Admission Rates for Patients with Multiple Chronic Conditions to pay-for-reporting, given the impact of the coronavirus disease 2019 (COVID-19) public health emergency (PHE) on these measures.